Why collaboration and an Integrated Product Development program are key to successful drug development

Employee training

Integrated product development (IPD) offers a way to mitigate the many issues that slow down the process of bringing a drug to market. A tendency to think of drug development as sequential and phase-driven means different activities are conducted in functional silos, which adversely affects the process.

In a recent BioProcess International special report, Mark Lane, Vice President of Development Consulting and Scientific Affairs at PharmaLex, explores how a global IPD program drives integrated collaboration and is an essential tool for improving efficiency, shortening timelines, reducing costs and improving the probability of regulatory approval and success in the marketplace. Download the special report to learn more.


This blog is intended to communicate PharmaLex’s capabilities which are backed by the author’s expertise. However, PharmaLex US Corporation and its parent, Cencora, Inc., strongly encourage readers to review the references provided with this article and all available information related to the topics mentioned herein and to rely on their own experience and expertise in making decisions related thereto as the article may contain certain marketing statements and does not constitute legal advice. 

Contact us for more information

Scroll to Top